Article
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
BMC biology - 20 Feb 2024
Dupain Célia, Gutman Tom, Girard Elodie, Kamoun Choumouss, Marret Grégoire, Castel-Ajgal Zahra, Sablin Marie-Paule, Neuzillet Cindy, Borcoman Edith, Hescot Ségolène, Callens Céline, Trabelsi-Grati Olfa, Melaabi Samia, Vibert Roseline, Antonio Samantha, Franck Coralie, Galut Michèle, Guillou Isabelle, Halladjian Maral, Allory Yves, Cyrta Joanna, Romejon Julien, Frouin Eleonore, Stoppa-Lyonnet Dominique, Wong Jennifer, Le Tourneau Christophe, Bièche Ivan, Servant Nicolas, Kamal Maud, Masliah-Planchon Julien
Abstract excerpt
BACKGROUND: High tumor mutational burden (TMB) was reported to predict the efficacy of immune checkpoint inhibitors (ICIs). Pembrolizumab, an anti-PD-1, received FDA-approval for the treatment of unresectable/metastatic tumors with high TMB as determined by the FoundationOne®CDx test. It remains to be determined how TMB can also be calculated using other tests. RESULTS: FFPE/frozen tumor samples from various...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.